Fermer le menu

About us


Alizé Pharma 3 develops innovative
therapeutic peptides for rare endocrine
and metabolic diseases

Our ambition is to become a leading rare disease
company with U.S. and European operations to support
global development of our products


We are building an innovative and
balanced portfolio of products targeting
important unmet needs

Our first two assets are AZP-3601, a PTH analog for hypoparathyroidism, and AZP-3404, a peptide leveraging the biology of IGFBP2 for the treatment of severe insulin resistance syndromes


Alizé Pharma 3 is
the third venture within
the Alizé Pharma organization

The first two Alizé Pharma companies
were acquired by Jazz Pharmaceuticals (2016)
and Millendo Therapeutics (2017)


Thierry Abribat, DVM, PhD –  Founder & CEO

Since 2007, Thierry Abribat has served as the founder and manager of the Alizé Pharma organization, a group of biotech companies based in Lyon, France. Over the last 10 years, he has founded and managed 3 companies, one of which, Alizé Pharma 2, was acquired by Jazz Pharmaceuticals (Nasdaq: JAZZ) and, another, Alizé Pharma, was acquired by Millendo Therapeutics. In addition, he is a board member of Millendo Therapeutics.  He began his career as a scientist at Sanofi, then at University of Montreal and as a consultant to the biopharmaceutical industry. He then held several executive positions with increasing responsibilities in drug development, business development and management at Theratechnologies (TSX: TH) and at OPi, Pharmaceuticals for Rare Diseases, until OPi’s acquisition by EUSA Pharma Inc. He holds a Doctorate of Veterinary Medicine and a Ph.D. from the National Polytechnic Institute of Toulouse.



Michael D Culler, PhD – CSO

Michael Culler is a biopharma research executive with extensive experience leading successful drug discovery projects, as well as the out-licensing of technology that has resulted in the creation of several successful startups.  He was formerly Vice President of Endocrinology Research for Ipsen, where he led programs in diverse endocrine areas that resulted in five compounds reaching clinical development.  He is a co-founder of Rhythm Pharmaceuticals, and led the pre-clinical programs that produced the key assets for both Rhythm (relamorelin and setmelanotide) and Radius Pharma (abaloparatide; Tymlos®).  Prior to joining industry, Dr. Culler conducted basic neuroendocrine research, both as a fellow at Tulane University School of Medicine and as a staff researcher at the National Institutes of Health.  Dr. Culler is an internationally recognized expert in endocrinology, metabolic disorders, rare diseases, and peptide therapeutics, and is a globally sought speaker on diverse topics, with over 200 publications and 22 patents. He has served on the editorial boards of Endocrinology and Endocrine, and is a member of the Expert List Committee of the World Anti-Doping Association (WADA).



Prof. Aart Jan van der Lely, MD PhD – Medical advisor

Aart Jan (AJ) van der Lely is Head of the Division of Endocrinology and Professor of Endocrinology at the Erasmus University MC in Rotterdam, The Netherlands. He also is Vice Head of the Dept. of Internal Medicine of the Erasmus University MC. His main research areas are pituitary diseases and the role of gut hormones in health and disease. Dr. Van der Lely serves or served on the editorial boards of Current Opinion in Endocrine and Metabolic Research, Clinical Endocrinology (Oxford), the Journal of Endocrinological Investigation, Clinical Interventions in Aging, Journal of Clinical Endocrinology and Metabolism, Endocrinology and Nature Reviews in Endocrinology. He is past-president of the Dutch Endocrine Society and past-secretary of the Section of Endocrinology of the European Union of Medical Specialists (UEMS). He served as Treasurer and is currently President of the European Society of Endocrinology. He recently joined the board of the Pituitary Society. Finally, he was also scientific advisor and co-founder of Alizé Pharma SAS in Lyon (now Millendo Therapeutics).



  • Felice Verduyn-van Weegen, Investment Manager at LSP, co-Chair
  • Naveed Siddiqi, Partner at Novo Ventures, co-Chair
  • Thierry Laugel, Managing Partner at Kurma Partners
  • Roy Amariglio, Principal at Orbimed
  • Iyona Rajkomar, Partner at Pontifax
  • Thierry Abribat, CEO Alizé Pharma 3
  • Mike Culler, CSO Alizé Pharma 3


  • René Kuijten, Managing Partner at LSP
  • Meredith Fisher, Partner at Partner Innovation Fund
  • Olivier Martinez, Senior Investment Director at Bpifrance
  • Mounia Chaoui, Associate Director at Turenne Santé

Our programs

AZP-3601, best-in-class PTH analog for hypoparathyroidism

Hypoparathyroidism, a severe disease resulting from insufficient parathyroid hormone (PTH) to maintain normal circulating calcium levels, affects over 80,000 patients in the US. It is associated with a large spectrum of symptoms, including mild to debilitating neuromuscular irritability, as well as neurocognitive and neuropsychiatric manifestations, due to low blood calcium levels.

AZP-3601 is a unique PTH analog designed specifically for PTH replacement therapy in hypoparathyroidism by academic partners at the Massachusetts General Hospital and Harvard Medical School. AZP-3601 potently interacts with a specific configuration of the PTH receptor that results in prolonged activation and effect on calcium metabolism. Preclinical studies have demonstrated that AZP-3601 is far more effective and longer-acting than natural PTH in increasing and maintaining circulating calcium levels without increasing urinary calcium excretion.

It is anticipated that the unique mechanism of action of AZP-3601 will translate into an enhanced safety and efficacy profile, and will make it a best-in-class therapy for treatment of this rare, but severe, endocrine disorder.


Key Academic Collaborators


Thomas J. Gardella – PhD
Associate Professor
in Medicine and Biochemiestry
MGH and Harvard Medical School




Michael Mannstadt – MD
Chief, Endocrine Unit MGH and
Associate Professor
Harvard Medical School


AZP-3404 for syndromes of severe insulin resistance

AZP-3404 is the first compound to harness the biology of Insulin-like Growth Factor Binding-Protein 2 (IGFBP-2), a physiological protein with key regulatory effects on glucose metabolism that are independent from its IGF-binding properties.

Alizé Pharma 3 and its academic partners at the University of North Carolina at Chapel Hill and the University of Maine have identified and optimized short peptide fragments of IGFBP-2 that retain its biological activities. AZP-3404 is a stabilized analog of one of these IGFBP-2 fragments with an improved pharmacokinetic profile. As a result, AZP-3404 is highly potent in restoring glucose control in preclinical models, including models of severe insulin resistance.

Based on its pharmacological profile, AZP-3404 is set to become a first-in-class therapy for the treatment of syndromes of severe insulin resistance, that include a range of rare diseases associated with high mortality and morbidity.


Key Academic Collaborators


David Clemmons – MD
University of North Carolina
at Chapel Hill (UNC)



Clifford Rosen – MD
Maine Medical center




Alizé Pharma 3 raises
€67 million ($75 million)
in Series A from a strong
international syndicate

En Fr


Alizé Pharma 3 to present data
from its AZP-3404 program
in syndromes of severe insulin
resistance at ENDO 2019

En Fr


Alizé Pharma 3 moves forward with building a transatlantic biopharmaceutical company focused on rare endocrine and metabolic diseases

En Fr

Contact us


Alizé Pharma 3

15, chemin du Saquin

Espace Européen, Building G

69 130 ECULLY



Tel +33 428 01 21 54